Independent
Tenure on this board
7.0 yrs
Meeting calendar
PRTA · Special meeting · Wednesday, November 19, 2025
Prothena Corp Public Ltd Co
13 nominees · 1 ballot item.
Approval of a special resolution to reduce the company's capital to create distributable reserves, enabling potential distributions including a share redemption program, subject to Irish High Court confirmation.
Market cap
$502M
1Y TSR
+66.5%
Board grade
C-
Record date
Sep 24, 2025
Filing
DEF 14A
Meeting concluded · Nov 19, 2025
Follow how the vote landed and what changed on Prothena Corp Public Ltd Co’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot1
- 1
Proposal No. 1 – APPROVAL OF A REDUCTION OF THE COMPANY’S CAPITAL TO CREATE DISTRIBUTABLE RESERVES
ManagementBoard: FORA special resolution to reduce the Company's capital by canceling and extinguishing the entire amount standing to the credit of the share premium account (or a lesser amount determined by the Board) to create distributable reserves, thereby giving the Board flexibility to return capital to shareholders (e.g., via a share redemption program) subject to Irish High Court confirmation.
Director elections
Nominees on the ballot13
Independent
Tenure on this board
14.5 yrs
Independent
Tenure on this board
14.5 yrs
Also a director at
Alkermes PLC (ALKS)
Independent
Tenure on this board
2.1 yrs
Independent
Tenure on this board
14.5 yrs
Helen S. Kim
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
13.5 yrs
Independent
Tenure on this board
2.4 yrs
Also a director at
Ultragenyx Pharmaceutical Inc (RARE)Structure Therapeutics Inc (GPCR)
Not independent
Tenure on this board
9.8 yrs
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
New nominee
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Rubric Capital Management LP | 9.6% | 5,000,000 | $49M |
| 2 | FMR LLC | 7.9% | 4,123,794 | $40M |
| 3 | FMR LLC | 6.5% | 3,427,424 | $33M |
| 4 | STATE STREET CORP | 3.7% | 1,938,498 | $19M |
| 5 | BlackRock, Inc. | 3.6% | 1,876,284 | $18M |
| 6 | D. E. Shaw Co., Inc.Activist | 3.3% | 1,735,591 | $17M |
| 7 | BlackRock, Inc. | 3.2% | 1,673,142 | $16M |
| 8 | ADAR1 Capital Management, LLC | 3.0% | 1,581,443 | $15M |
| 9 | ACADIAN ASSET MANAGEMENT LLC | 3.0% | 1,547,593 | $15M |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.8% | 1,445,979 | $14M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Prothena Corp Public Ltd Co’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Trubridge IncTBRG
Special meeting·Jul 7, 2026·$393M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Reference
Frequently asked questions
- When is the Prothena Corp Public Ltd Co 2025 special meeting?
- Prothena Corp Public Ltd Co (PRTA) holds its 2025 special shareholder meeting on Wednesday, November 19, 2025.
- What is the record date for the Prothena Corp Public Ltd Co 2025 meeting?
- The record date for the Prothena Corp Public Ltd Co 2025 meeting is Wednesday, September 24, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Prothena Corp Public Ltd Co's 2025 meeting?
- The board is presenting 13 director nominees at the Prothena Corp Public Ltd Co 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Prothena Corp Public Ltd Co 2025 meeting?
- Shareholders will vote on 1 proposal at the Prothena Corp Public Ltd Co 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.